Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar

publication date: Dec 13, 2018

Suzhou Innovent Biologics reported its Avastin biosimilar produced positive results in two China clinical trials. IBI305, a VEGF inhibitor, met its primary endpoints in two randomized clinical trials that compared the candidate to Roche's Avastin: 1) a Phase III trial in 450 patients with advanced non-squamous non-small cell lung cancer (NSCLC) and 2) a pharmacokinetic study in 100 healthy volunteers. Innovent plans to release details from the two trials in future scientific journals and conferences. More details....

Stock Symbol: (HKEX: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.